Acorn Genetics
Raising nowOperatingACORN GENETICS INC.
Biotech · Chicago, IL
Acorn Genetics is commercializing SENTRI, a portable DNA testing system that helps businesses detect contamination and quality issues on-site rather than waiting for lab results. We’re the preferred testing supplier for the Independent Brewers Alliance and a listed supply partner with the Beverage Federation, a direct channel to more than 1,300 breweries, with plans to expand into food safety, agriculture, water testing, biofuels, and healthcare.
This company has an open fundraising round.
Financials
FY2024–FY2025 · from SEC filings · hover any figure for its sourceFigures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited, as the filing’s own report or certification states it. A dashed pill marked * is inferred instead: the SEC minimum for an offering that size, which the issuer may have exceeded. No pill means we couldn’t tell. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.
Valuation over rounds
Valuation caps on SAFE / convertible note roundsDashed amber bars are a SAFE or convertible note's valuation cap — the most it converts at, not what the company is worth.
Cap table
Principal holders% as the filing states it, Sep 28, 2026
- Ana CornellCommon Stock88.0%of
From the company's SEC filings: share counts per class, each class's voting and conversion terms, and the holders of 20% or more that Form C requires (officers and 10%+ holders on Form 1-A). Filings name only large holders, so most owners — including crowd investors — are not listed, and a holder's percentage may be of its own class rather than of the whole company. Prices and crowd share counts are in today's share terms — adjusted for splits and conversions since they were sold. Hover a figure for its filing.
Fundraising history
Team
5 people
Sequencing expert with over 20 years of experience across Pacific Biosciences, Veracyte, and LevitasBio. He holds a PhD in Biochemistry from UCSF and is a named inventor on dozens of sequencing patents.
Names and titles as disclosed on StartEngine, SEC Form C. Bios and photos come from the platform campaign page and may be out of date.
Reg CF annual-report compliance
never closed a Reg CF raise
Reg CF issuers must file a Form C-AR each year until a Rule 202(b) termination trigger is met.
SEC filings
- Form CSep 28, 20260002142534-26-000002EDGAR
About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.